Tag: pharmaceuticals
-
Challenge Seeks Extended Release Intravenous Drug Delivery
20 February 2015. A new challenge on InnoCentive is seeking ways to administer high-dose drugs through intravenous delivery, but releasing the therapy in the patient for a period of 8 to 10 hours. The competition has a purse of $30,000 and deadline of 21 March 2015. InnoCentive in Waltham, Massachusetts conducts open-innovation, crowdsourcing competitions for…
-
RNA Flu Therapy Clinical Trials Complete Enrollment
19 February 2015. Two late-stage clinical trials testing an influenza treatment that disrupts a virus’s genetic replication ability finished recruiting more than 2,000 participants worldwide. The trials are being conducted by MediVector Inc., a drug development company in Boston, for Joint Project Manager Medical Countermeasure Systems, an office in the U.S. Department of Defense developing…
-
European Patent Issued for Rare Liver Disease Drug
18 February 2015. Synageva BioPharma Corp., a biopharmaceutical company developing therapies for rare diseases, received a European patent on its treatment for lysosomal acid lipase deficiency, an inherited disease causing severe disruptions and injuries to the liver. The European Patent Office issued patent number EP2613798 B1 on 11 February to inventor Anthony Quinn, Synageva’s chief…
-
Flu Vaccine Shown to Protect Against Avian Influenza
18 February 2015. Researchers at University of Chicago and Mount Sinai medical centers found people who receive the seasonal flu vaccine also generate antibodies that in lab cultures and animals act against avian (H7N9) and other influenza strains. The team led by Chicago’s Patrick Wilson and Mount Sinai’s Florian Krammer published its findings yesterday in the Journal…
-
Thyroid Cancer Drug Approved by FDA
16 February 2015. The U.S. Food and Drug Administration approved on Friday a drug for differentiated thyroid cancers, where the cancer continues to grow despite treatments with radioactive iodine. The drug, lenvatinib, is marketed by Eisai Inc. in Woodcliffe, New Jersey, under the brand name Lenvima. The thyroid gland helps the body regulate metabolism, using…
-
Intrexon Acquires Biopharm Company for $60M
13 February 2015. Intrexon Corp., a biotechnology company in Gaithersburg, Maryland specializing in synthetic biology, is acquiring ActoGeniX, developing biologic therapies from engineered microbes. Under the deal, stockholders of ActoGeniX, based in Ghent, Belgium, are receiving $30 million in cash plus another $30 million in Intrexon stock. ActoGeniX develops therapies from engineered microbes, particularly Lactococcus…
-
Janssen, Foundation to Devise Diabetes Prevention Strategy
12 February 2015. Janssen Research and Development, a division of Johnson & Johnson, and JDRF plan to investigate new ways to diagnose early conditions and prevent the onset of type 1 diabetes. Financial details of the collaboration between Janssen and JDRF, a foundation supporting research on type 1 diabetes, were not disclosed. Type 1 diabetes is…
-
Foundation, Pfizer Collaborate on Alzheimer’s Targets
11 February 2015. Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are joining forces to sponsor research to find new Alzheimer’s disease drug targets. Financial details of the collaboration were not revealed. The foundation and Pfizer plan to invest in project teams of Pfizer and academic scientists to translate academic research into candidates…
-
Genzyme Licensing Gene Therapies from Biotech Start-Up
11 February 2015. Voyager Therapeutics, a designer of gene therapies for central nervous system diseases, is licensing some of its treatments now in development to Genzyme Corp., a biotechnology subsidiary of the drug maker Sanofi. The deal is expected to bring the one year-old spin-off from four university research labs as much as $845 million.…
-
Biotech, Hospira to Partner on Biosimilar for Eye Disease
10 February 2015. Pfenex Inc., a biotechnology company in San Diego, is licensing its lead product to treat age-related macular degeneration to biologic therapy maker Hospira. The deal can bring Pfenex as much as $342 million, plus royalties on sales of products from the collaboration, over at least the next five years. Age-related macular degeneration is…